DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis
Predicts overall survival in primary myelofibrosis. Can be applied at any time during the disease course.
Score interpretation
Low risk (DIPSS 0). Median OS not reached.
→ Watch and wait; symptom management. JAK inhibitor if symptomatic.
Intermediate-1 risk (DIPSS 1–2). Median OS ~14.2 years.
→ Symptom control. Consider JAK inhibitors for splenomegaly/symptoms.
Intermediate-2 risk (DIPSS 3–4). Median OS ~4 years.
→ JAK inhibitor therapy (ruxolitinib). Consider allo-SCT in eligible patients.
High risk (DIPSS 5–6). Median OS ~1.5 years.
→ Urgent haematology review. JAK inhibitor; allo-SCT if eligible; clinical trial. Supportive care.
Interpretation bands for the DIPSS. Apply clinical judgement and local guidance.
References
- Passamonti F, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
- Gangat N et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
Related
Curated clinical cross-links plus same-class fallbacks.
- Fong Clinical Risk Score for CRC Liver Metastases · Cancer Prognosis
- FLIPI — Follicular Lymphoma International Prognostic Index · Cancer Prognosis
- CLL-IPI (International Prognostic Index for CLL) · Cancer Prognosis
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- WPSS — WHO Prognostic Scoring System for MDS · Cancer Prognosis
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
- Ruxolitinib Cream · Topical JAK1/2 Inhibitor
- Ruxolitinib · JAK1/2 Inhibitor
- Milrinone · Inodilator — Phosphodiesterase III Inhibitor
- Tocilizumab (ICU — Cytokine Storm / COVID-19) · IL-6 Receptor Inhibitor
- Methylene Blue · Guanylate Cyclase / Nitric Oxide Pathway Inhibitor
- Dantrolene sodium · Skeletal muscle relaxant (RyR1 inhibitor)
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.